Abstract: Gels and polymers comprising a polypeptide bound to a polysaccharide are disclosed. Specific polypeptides include, but are not limited to, polypeptides that comprise glutamine or tyrosine residues. Specific polysaccharides include, but are not limited to, chitosan. Gels and polymers of the invention can be used for the in vitro and in situ formation of protein-polysaccharide conjugates. Methods of making polypeptide/polysaccharide gels and polymers are also disclosed.

Abstract: A method for introducing and expressing genes in animal cells, in which the animal cells are transfected with bacterial blebs containing a eukaryotic expression cassette encoding the gene. Bacterial blebs comprising a eukaryotic expression cassette, wherein the bacterial blebs are derived from gram negative bacteria.

Abstract: The present invention relates to a two-stage biofilter reactor system for removing nitrogenous compounds from a recirculating aquaculture system. The system includes a aerobic nitrification unit and a downstream anaerobic denitrification unit, wherein both units have a mobile bed of suspended media whereon bacteria can grow and reduce nitrate and/or ammonia levels in the recirculating aquaculture system. Use of the two-stage system has the advantage of reducing the water exchange rates and consumption of salt when maintaining a saline effluent.

Abstract: The present invention relates to the downregulation of surface receptor CCR5 expression through manipulation of the cell cycle in activated lymphocytes by administering a composition that arrests the G1 phase of the cell cycle, thereby reducing receptor sites for entry of HIV into T cells, and thus, the effects of HIV. Further, compositions are disclosed that include at least one G1 phase arresting agent and at least one antiviral agent, wherein the combination of agents synergistically enhances the activity of the antiviral agent.

Abstract: A method of enhancing a culturing characteristic of fish larvae, including administering to said larvae in a nutritional diet essential fatty acids including DHA and AA in a ratio effective to enhance the culturing characteristic of such fish larvae relative to a corresponding nutritional diet lacking DHA and AA. The culturing characteristic may be at least one of stress resistance, immunoresistance, hatching rate, and growth rate. In a preferred aspect, the DHA and AA together comprise from about 10 to about 30% of total fatty acids in enrichment lipids, and the dietary ratio of DHA: AA is less than 10.

Abstract: The present invention to amino acid sequences of proteins that are associated with apoptosis and the use of these proteins in the diagnosis, prevention and treatment of disorders associated with abnormal cell proliferation and apoptosis. The invention relates as well to nucleotide sequences encoding the peptides, recombinant vectors carrying the sequences, recombinant host cells including either the sequences or vectors, and recombinant peptides. The invention further includes methods for using the nucleotide sequences and recombinant peptides in diagnostic and therapeutic applications.

Abstract: Disclosed are strains of actinomycetes that produce manzamines or derivatives thereof, methods of isolating said strains, and a 16S rRNA useful in identifying manzamine-producing bacteria.

Abstract: The present invention relates to sub-unit vaccines comprising structural polypeptides of Infectious Pancreatic Necrosis Virus (IPNV) comprising structural proteins VP2 and VP3 folded as an empty IPNV viral capsid that approximates the size and structural conformation of native IPNV virus.

Abstract: The present invention relates to a composition and method for enhancing the efficacy of a vaccine in a subject treated with the vaccine by administering to the subject an antigen in conjunction with a chemokine.

Abstract: The invention relates to chimeric molecules comprising a virus coat sequence and a receptor sequence that can inter-act with each other to form a complex that is capable of binding a co-receptor. Such chimeric molecules therefore exhibit functional properties characteristic of a receptor-coat protein complex and are useful as agents that inhibit virus infection of cells due to occupancy of a co-receptor present on the cell. In particular aspects, the chimeric polypeptide includes an immunodeficiency virus envelope polypeptide, such as that of HIV, SIV, FIV, FeLV, FPV and herpes virus. Receptor sequences suitable for use in a chimeric polypeptide include, for example, CD4 D1D2 and CD4M9 sequences.

Abstract: The present inventors have found that certain preparations containing LPS and/or lipid A variants, derivatives, and/or analogs demonstrate non-pyrogenic properties and exhibit anti-viral activities. In particular, non-pyrogenic preparations of LPS, lipid A, LPS antagonists and lipid A antagonists, and derivatives thereof induce ? chemokine secretion, such as MIP-1?, but not proinflammatory cytokines, such as TNF?, IL-1? and IL-6. Non-pyrogenic preparations of the invention have been demonstrated by the Applicant to suppress HIV replication in human peripheral blood monocytes, as described by way of example herein. The present invention provides preparations of LPS or lipid A variants, analogs and derivatives of decreased or absent pyrogenicity which can be used as therapeutics for the treatment or prevention of immunodeficiency virus infection and its consequences.

Abstract: The present invention relates to fractions of sources and or preparations of human chorionic gonadotropin, such as fractions of human early pregnancy urine, which fractions have anti-HIV activity. The present invention further relates to pharmaceutical compositions comprising such fractions for treating the effects of HIV infection.

Abstract: A caged non-steroidal ecdysome memetic (NSE) compound and a method for producing free NSE by subjecting the charged NSE to UV irradiation.

Abstract: The present invention provides a method of differential display of prokaryotic messages RNA by RTPCR, the method comprising the steps of: adding a first primer mixture to a first nucleic acid sample including a first mixture of mRNA to form a first primer/first nucleic acid sample mixture; adding the first primer mixture to a second nucleic acid sample including a first mixture of mRNA to form a first primer/second nucleic acid sample mixture; incubating the first primer/first nucleic acid sample mixture to produce a first population of cDNA; incubating the first primer/second nucleic acid sample mixture to produce a second population of cDNA; adding a second primer to the first population of cDNA to form a second primer/first population of cDNA mixture; adding the second primer mixture to the second population of cDNA to form a second primer/second population of cDNA mixture; amplifying the second primer/first population of cDNA mixture to produce a third population of cDNA; amplifying the second primer/seco

Abstract: LPS preparations, isolated from gram negative bacterial strains that contain at least one mutation in at least one of the htrB and msbB genes, and methods and therapeutics related thereto. The LPS preparations display both LPS antagonist and adjuvant activities.

Abstract: The present invention relates to &bgr;-hCG, particularly &bgr;-hCG proteins having a sequence of amino acids 41-54, 45-54, 47-53, 45-57 and 45-58 and analogs and derivatives thereof. The invention further relates to methods of treatment and prevention of HIV infection by administration of a therapeutic compound of the invention. Such therapeutic compounds include hCG, &bgr;-hCG and &bgr;-hCG peptides, analogs and derivatives of hCG, &bgr;-hCG and &bgr;-hCG peptides, and nucleic acids encoding hCG, &bgr;-hCG and &bgr;-hCG peptides. In a preferred embodiment, &bgr;-hCG peptides, particularly &bgr;-hCG peptides of amino acids 47-53, 45-57 or 45-58 are administered to a subject for treatment or prevention of HIV infection in that subject. The invention also provides methods for screening hCG preparations for activity in treating or preventing HIV infection. Pharmaceutical compositions and methods of administration of Therapeutics are also provided.

Abstract: The present invention relates to peptides of one or more portions of the human chorionic gonadotropin &bgr;-chain as well as methods for treatment of cancer, using human chorionic gonadotropin, employing the &bgr;-chain of human chorionic gonadotropin, peptides containing a sequence of one or more portions of the &bgr;-chain of human chorionic gonadotropin and derivatives and analogues thereof. The invention further relates to fractions of sources and or preparations of human chorionic gonadotropin, such as fractions of human early pregnancy urine, which fractions have anti-cancer activity. The present invention further relates to pharmaceutical compositions for treating cancer.

Abstract: The present invention relates to a transition metal-ligand complex that shows changes in its luminescence lifetime characteristic and/or luminescence intensity as a function of the polarity and/or hydrogen bonding properties of its environment, and a sensor, probe, system and method based on the complex for detecting the presence, amount or concentration of a polar solvent in a medium.

Abstract: The invention provides transgenic animals comprising a lentiviral transgene, such as an HIV transgene. Also within the scope of the invention are cells and eggs from the transgenic animal. Further included are methods for identifying therapeutic compounds for preventing lentiviral infection and treating associated disease (e.g. AIDS).

Abstract: The present invention provides for a recombinant insect larvae and a process of manufacturing proteins utilizing insect larvae that allows for the selection of individual larvae for harvest at the point of their optimal expression of a protein of interest. This invention also provides for a process to manufacture proteins in larvae that does not require synchronization of the infection, growth and harvest larvae to optimally manufacture a protein of interest. The invention further provides for a process of producing interleukin-2 in larvae.